Loading...
Belatacept in kidney transplant patients with systemic lupus erythematosus
OBJECTIVES: Lupus nephritis (LN) requires renal replacement therapy in 10%–30% of patients. About 30% of these patients receive a kidney transplant. Belatacept is a second-generation, selective, T-cell co-stimulator blocker (inhibits cytotoxic, T-lymphocyte antigen 4, CTLA-4) used as an alternative...
Na minha lista:
| Udgivet i: | Lupus Sci Med |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6928461/ https://ncbi.nlm.nih.gov/pubmed/31908816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2019-000355 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|